Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patients

被引:2
|
作者
Gualano, Bruno [1 ,2 ]
Saad, Carla G. S. [3 ]
Sieczkowska, Sofia M. [1 ]
Lemes, Italo Ribeiro [1 ]
da Silva, Rafael Pires [1 ]
Pinto, Ana J. [1 ,4 ]
Mazzolani, Bruna C. [1 ]
Smaira, Fabiana, I [1 ]
Gil, Saulo [1 ]
Oliveira-Junior, Gersiel [1 ]
Aikawa, Nadia E. [3 ]
Medeiros-Ribeiro, Ana C. [3 ]
Silva, Clovis A. [3 ,5 ]
Yuki, Emily F. N. [3 ]
Pasoto, Sandra G. [3 ]
Pereira, Rosa Maria R. [3 ]
Shinjo, Samuel K. [3 ]
Andrade, Danieli C. O. [3 ]
Sampaio-Barros, Percival D. [3 ]
Roschel, Hamilton [1 ]
Bonfa, Eloisa [3 ]
机构
[1] Univ Sao Paulo, Fac Med FMUSP, Sch Phys Educ & Sport, Div Rheumatol,Appl Physiol & Nutr Res Grp, Sao Paulo, Brazil
[2] Univ Sao Paulo, Food Res Ctr, Sao Paulo, Brazil
[3] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Div Rheumatol, Sao Paulo, Brazil
[4] Univ Colorado, Sch Med, Metab & Diabet & Anschutz Hlth & Wellness Ctr, Div Endocrinol, Anschutz Med Campus, Aurora, CO USA
[5] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Inst Crianca & Adolescente,Pediat Rheumatol Unit, Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
COVID-19; immunosuppression; physical activity; resistance exercise; Sinovac-CoronaVac; ECCENTRIC EXERCISE; PHYSICAL-ACTIVITY; RESPONSES; EFFICACY; ANTIBODY; ADJUVANT;
D O I
10.1152/japplphysiol.00015.2022
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
This randomized controlled study aimed to investigate whether a single bout of exercise before the homologous booster dose of a SARS-CoV-2 inactivated vaccine could enhance immunogenicity in patients with spondyloarthritis. We selected 60 consecutive patients with spondyloarthritis (SpA). Patients assigned to the intervention group performed an exercise bout comprising three exercises. Then, they remained at rest for 1 h before vaccination. The control group remained at rest before vaccination. Immunogenicity was assessed before (Pre) and 1 mo after (Post) the booster using seropositivity rates of total anti-SARS-CoV-2 S1/S2 IgG, geometric mean titers of anti-S1/S2 IgG (GMT), frequency of neutralizing antibodies (NAb) positivity, and NAb activity. At Pre, 16 patients from the exercise group and 16 patients from the control group exhibited seropositivity for IgG (59% vs. 57.1%), and 1 mo after the booster dose, seropositivity occurred in 96% versus 100% of the cases. Only 10 patients from the exercise group and 12 patients from the control group showed positive NAb serology at Pre (37% vs. 42.8%). One month following the booster, NAb positivity was 96% versus 93%. GMT was comparable between groups at Pre. At Post, GMT increased similarly in both groups. Likewise, NAb activity was similar between groups at Pre and increased similarly in both of them as a result of the booster (47.5% vs. 39.9%). In conclusion, a single bout of exercise did not enhance immunogenicity to a homologous booster dose of an inactivated SARS-CoV-2 vaccine among patients with spondyloarthritis. NEW & NOTEWORTHY We tested the role of exercise as an adjuvant to a booster of a COVID-19 vaccine. Immunocompromised patients were immunized after an acute bout of exercise or not. Patients exhibited an excellent immunogenicity in response to
引用
收藏
页码:682 / 688
页数:7
相关论文
共 50 条
  • [1] Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis
    Zhan, Haoting
    Yang, Li
    Liu, Yongmei
    Li, Haolong
    Li, Xiaomeng
    Wang, Haibin
    Cao, Jinfeng
    Kang, Shuhui
    Guo, Xinru
    Dai, Erhei
    Li, Yongzhe
    JOURNAL OF INFECTION, 2023, 86 (05) : e138 - e141
  • [2] Acceptance, safety, and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in patients with primary biliary cholangitis
    Li, Haolong
    Wang, Xu
    Wang, Siyu
    Feng, Xinxin
    Wang, Li
    Li, Yongzhe
    HELIYON, 2024, 10 (07)
  • [3] Safety and immunogenicity of the third (booster) dose of inactivated and recombinant protein SARS-CoV-2 vaccine for patients with endocrine-related cancer
    Han, Shanshan
    Yang, Yuping
    Wang, Tingrui
    Song, Rui
    Hu, Daixing
    Peng, Mingli
    Lin, Zijing
    Deng, Qin
    Ren, Hong
    Ming, Jia
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [4] Willingness-to-pay for a booster dose of inactivated SARS-CoV-2 vaccine in Taizhou, China
    Tung, Tao-Hsin
    Lin, Xiao-Qing
    Chen, Yan
    Zhang, Mei-Xian
    Zhu, Jian-Sheng
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (06)
  • [5] Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies
    Kandeil, Ahmed
    Mostafa, Ahmed
    Hegazy, Rehab R.
    El-Shesheny, Rabeh
    El Taweel, Ahmed
    Gomaa, Mokhtar R.
    Shehata, Mahmoud
    Elbaset, Marawan A.
    Kayed, Ahmed E.
    Mahmoud, Sara H.
    Moatasim, Yassmin
    Kutkat, Omnia
    Yassen, Noha N.
    Shabana, Marwa E.
    GabAllah, Mohamed
    Kamel, Mina Nabil
    Abo Shama, Noura M.
    El Sayes, Mohamed
    Ahmed, Amira N.
    Elalfy, Zahraa S.
    Mohamed, Bassim M. S. A.
    Abd El-Fattah, Safa N.
    El Hariri, Hazem Mohamed
    Abdel Kader, Mona
    Azmy, Osama
    Kayali, Ghazi
    Ali, Mohamed A.
    VACCINES, 2021, 9 (03) : 1 - 15
  • [6] Evaluation of Immunogenicity of an Inactivated SARS-CoV-2 Vaccine Prototype in vitro
    Hancharou, Andrei
    Antonevich, N.
    Pozniak, T.
    Babrukevich, Darya
    Semizhon, P.
    Scheslenok, E.
    Rynda, A.
    Timohina, O.
    Minich, Y.
    DuBuske, Lawrence
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB96 - AB96
  • [7] Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series
    Assawasaksakul, Theerada
    Sathitratanacheewin, Seelwan
    Vichaiwattana, Preeyaporn
    Wanlapakorn, Nasamon
    Poovorawan, Yong
    Kittanamongkolchai, Wonngarm
    RMD OPEN, 2021, 7 (03):
  • [8] Humoral Immune Response in Inactivated SARS-CoV-2 Vaccine: When Should a Booster Dose be Administered?
    Kara, Ertan
    Tanir, Ferdi
    Demirhindi, Hakan
    Mete, Burak
    Kibar, Filiz
    Cetiner, Salih
    Candevir, Aslihan
    Inaltekin, Ayse
    MIKROBIYOLOJI BULTENI, 2022, 56 (03): : 566 - 573
  • [9] Inactivated vaccine for SARS-CoV-2
    Emma Risson
    Nature Reviews Immunology, 2020, 20 : 353 - 353
  • [10] Inactivated vaccine for SARS-CoV-2
    Risson, Emma
    NATURE REVIEWS IMMUNOLOGY, 2020, 20 (6) : 353 - 353